Altimmune's Pemvidutide Shows Significant Metabolic Risk Improvements
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- Clinical Trial Results: At the EASL 2026 Congress, Altimmune presented 48-week data from the IMPACT Phase 2b trial, revealing that the pemvidutide treatment group experienced a 23.7% reduction in triglycerides and a 15.4% reduction in total cholesterol, indicating significant efficacy in improving cardiovascular risk factors in patients with metabolic dysfunction-associated steatohepatitis (MASH).
- Weight and Blood Pressure Improvements: Patients receiving pemvidutide 1.8 mg showed a 7.5% weight loss, a 3.0 kg/m² reduction in body mass index, a 5.3 cm decrease in waist circumference, and improvements in systolic and diastolic blood pressure by 4.0 mmHg and 2.2 mmHg respectively, highlighting the drug's broad impact on multiple metabolic risk factors.
- Safety and Tolerability: Over the 48-week treatment period, pemvidutide maintained a favorable safety and tolerability profile, with only about 1% of patients discontinuing due to adverse events, most of which were mild to moderate, indicating the drug's potential for clinical application without significant safety concerns.
- Future Research Plans: Altimmune is set to initiate the PERFORMA Phase 3 trial in the second half of 2026 to further assess the efficacy and safety of pemvidutide in MASH patients, demonstrating the company's confidence in the drug's potential impact in the treatment landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALT
Wall Street analysts forecast ALT stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.070
Low
12.00
Averages
16.00
High
20.00
Current: 3.070
Low
12.00
Averages
16.00
High
20.00
About ALT
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed Phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altimmune Releases New Data on Pemvidutide for MASH Treatment
- Clinical Trial Data: Altimmune presented 48-week data from the Phase 2b IMPACT trial for Pemvidutide at the EASL congress, demonstrating significant efficacy in 212 patients with metabolic dysfunction-associated steatohepatitis (MASH).
- Cardiometabolic Risk Reduction: Patients receiving a daily dose of 1.8 mg of Pemvidutide showed a 23.7% reduction in triglyceride levels and a 15.4% decrease in cholesterol, indicating the drug's potential in lowering cardiometabolic risks.
- Weight and Circumference Changes: The average patient experienced a 7.5% weight loss, a 5.3 cm reduction in waist circumference, and a decline in body mass index by 30 kg/m², highlighting Pemvidutide's positive impact on weight management.
- Future Trial Plans: The company plans to conduct the Phase 3 PERFORMA trial to further evaluate Pemvidutide's broad metabolic and liver effects while also advancing its research for treating alcohol use disorder and alcohol-associated liver disease.
See More
Altimmune's Pemvidutide Shows Significant Metabolic Risk Improvements
- Clinical Trial Results: At the EASL 2026 Congress, Altimmune presented 48-week data from the IMPACT Phase 2b trial, revealing that the pemvidutide treatment group experienced a 23.7% reduction in triglycerides and a 15.4% reduction in total cholesterol, indicating significant efficacy in improving cardiovascular risk factors in patients with metabolic dysfunction-associated steatohepatitis (MASH).
- Weight and Blood Pressure Improvements: Patients receiving pemvidutide 1.8 mg showed a 7.5% weight loss, a 3.0 kg/m² reduction in body mass index, a 5.3 cm decrease in waist circumference, and improvements in systolic and diastolic blood pressure by 4.0 mmHg and 2.2 mmHg respectively, highlighting the drug's broad impact on multiple metabolic risk factors.
- Safety and Tolerability: Over the 48-week treatment period, pemvidutide maintained a favorable safety and tolerability profile, with only about 1% of patients discontinuing due to adverse events, most of which were mild to moderate, indicating the drug's potential for clinical application without significant safety concerns.
- Future Research Plans: Altimmune is set to initiate the PERFORMA Phase 3 trial in the second half of 2026 to further assess the efficacy and safety of pemvidutide in MASH patients, demonstrating the company's confidence in the drug's potential impact in the treatment landscape.
See More
Truist Initiates Coverage on VKTX with Buy Rating and $83 Price Target
- Analyst Rating Boost: Truist has initiated coverage on Viking Therapeutics (VKTX) with a ‘Buy’ rating and an $83 price target, indicating a potential upside of 162% from current levels, reflecting strong market confidence in its growth prospects.
- Weight Loss Market Dynamics: Eli Lilly (LLY) saw its stock price climb nearly 25% over the past month, making it the strongest performer among major obesity drug stocks, highlighting investor recognition of its sustained demand for GLP-1 therapies and market leadership.
- Viking's Competitive Edge: Truist emphasized that Viking's VK2735 drug achieved a 14.7% weight loss in just 13 weeks, with patients continuing to lose weight, showcasing its differentiated competitive advantage in the obesity drug market that could attract more patients.
- Lilly's Market Expansion: Lilly recently announced deals worth up to $3.8 billion with three vaccine developers, further expanding its footprint in infectious diseases and long-term healthcare infrastructure, indicating growth potential beyond its obesity drug portfolio.
See More
Altimmune to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Altimmune will participate in the 2026 Jefferies Global Healthcare Conference on June 4, 2026, with a fireside chat at 12:50 PM ET in New York, showcasing its latest advancements in liver disease treatment and attracting investor interest.
- Key Conference Dates: Following this, Altimmune will also attend the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, with a fireside chat at 8:00 AM ET in Miami Beach, further enhancing the company's visibility among investors.
- Product Development Context: The pemvidutide being developed by Altimmune is a unique dual-action therapy targeting glucagon and GLP-1 receptors in a balanced 1:1 ratio, aimed at treating serious liver diseases such as metabolic dysfunction-associated steatohepatitis, indicating significant market potential.
- Information Access Channels: Investors can access the webcast of the fireside chats via the Events section of the Altimmune website, enhancing interaction with investors and improving transparency and trust.
See More
Altimmune Q1 2026 Earnings Call Insights
- Successful Financing: Altimmune completed an oversubscribed public offering in April, raising $225 million in gross proceeds, resulting in a cash balance of approximately $535 million as of April 30, which provides the company with sufficient funds to support its clinical programs through the critical data readout in 2029.
- Clinical Trial Progress: The company expects to initiate its global Phase III MASH trial, named PERFORMA, in the second half of this year, with data serving as the basis for regulatory submissions in multiple regions, marking a significant milestone in its global development strategy.
- Financial Performance: In Q1 2026, R&D expenses totaled $16.2 million, G&A expenses were $8.1 million, and the net loss amounted to $22.6 million, or $0.18 per share, indicating financial pressure while advancing clinical development.
- Future Outlook: Altimmune plans to report top-line data from the Phase II trial in alcohol use disorder next quarter and expects to complete enrollment for the RESTORE trial in ALD by Q3 2026, demonstrating positive progress across multiple clinical trials and confidence in future growth.
See More
Altimmune Reports Q1 2026 Financial Results and Progress on Pemvidutide
- Successful Financing: Altimmune completed an oversubscribed public offering in April, raising $225 million, significantly strengthening its financial foundation with a cash balance of approximately $535 million, ensuring funding for the MASH Phase III clinical trial in 2026.
- Clinical Trial Progress: The company plans to initiate the global Phase III clinical trial for MASH, named PERFORMA, in the second half of 2026, having submitted the final study protocol to the FDA, which is expected to support regulatory submissions across multiple regions, showcasing strategic positioning in liver disease treatment.
- Market Demand Analysis: Market research indicates that pemvidutide demonstrates favorable tolerability and efficacy in MASH patients, expected to address the growing unmet medical needs in this area, further solidifying Altimmune's competitive position in the biopharmaceutical market.
- Future Outlook: Altimmune is focused on executing its strategy, with top-line data from the AUD Phase II trial expected next quarter, further advancing the clinical development of pemvidutide and aiming to create long-term value for shareholders.
See More
Altimmune Releases New Data on Pemvidutide for MASH Treatment
- Clinical Trial Data: Altimmune presented 48-week data from the Phase 2b IMPACT trial for Pemvidutide at the EASL congress, demonstrating significant efficacy in 212 patients with metabolic dysfunction-associated steatohepatitis (MASH).
- Cardiometabolic Risk Reduction: Patients receiving a daily dose of 1.8 mg of Pemvidutide showed a 23.7% reduction in triglyceride levels and a 15.4% decrease in cholesterol, indicating the drug's potential in lowering cardiometabolic risks.
- Weight and Circumference Changes: The average patient experienced a 7.5% weight loss, a 5.3 cm reduction in waist circumference, and a decline in body mass index by 30 kg/m², highlighting Pemvidutide's positive impact on weight management.
- Future Trial Plans: The company plans to conduct the Phase 3 PERFORMA trial to further evaluate Pemvidutide's broad metabolic and liver effects while also advancing its research for treating alcohol use disorder and alcohol-associated liver disease.
See More
Altimmune's Pemvidutide Shows Significant Metabolic Risk Improvements
- Clinical Trial Results: At the EASL 2026 Congress, Altimmune presented 48-week data from the IMPACT Phase 2b trial, revealing that the pemvidutide treatment group experienced a 23.7% reduction in triglycerides and a 15.4% reduction in total cholesterol, indicating significant efficacy in improving cardiovascular risk factors in patients with metabolic dysfunction-associated steatohepatitis (MASH).
- Weight and Blood Pressure Improvements: Patients receiving pemvidutide 1.8 mg showed a 7.5% weight loss, a 3.0 kg/m² reduction in body mass index, a 5.3 cm decrease in waist circumference, and improvements in systolic and diastolic blood pressure by 4.0 mmHg and 2.2 mmHg respectively, highlighting the drug's broad impact on multiple metabolic risk factors.
- Safety and Tolerability: Over the 48-week treatment period, pemvidutide maintained a favorable safety and tolerability profile, with only about 1% of patients discontinuing due to adverse events, most of which were mild to moderate, indicating the drug's potential for clinical application without significant safety concerns.
- Future Research Plans: Altimmune is set to initiate the PERFORMA Phase 3 trial in the second half of 2026 to further assess the efficacy and safety of pemvidutide in MASH patients, demonstrating the company's confidence in the drug's potential impact in the treatment landscape.
See More
Truist Initiates Coverage on VKTX with Buy Rating and $83 Price Target
- Analyst Rating Boost: Truist has initiated coverage on Viking Therapeutics (VKTX) with a ‘Buy’ rating and an $83 price target, indicating a potential upside of 162% from current levels, reflecting strong market confidence in its growth prospects.
- Weight Loss Market Dynamics: Eli Lilly (LLY) saw its stock price climb nearly 25% over the past month, making it the strongest performer among major obesity drug stocks, highlighting investor recognition of its sustained demand for GLP-1 therapies and market leadership.
- Viking's Competitive Edge: Truist emphasized that Viking's VK2735 drug achieved a 14.7% weight loss in just 13 weeks, with patients continuing to lose weight, showcasing its differentiated competitive advantage in the obesity drug market that could attract more patients.
- Lilly's Market Expansion: Lilly recently announced deals worth up to $3.8 billion with three vaccine developers, further expanding its footprint in infectious diseases and long-term healthcare infrastructure, indicating growth potential beyond its obesity drug portfolio.
See More
Altimmune to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Altimmune will participate in the 2026 Jefferies Global Healthcare Conference on June 4, 2026, with a fireside chat at 12:50 PM ET in New York, showcasing its latest advancements in liver disease treatment and attracting investor interest.
- Key Conference Dates: Following this, Altimmune will also attend the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, with a fireside chat at 8:00 AM ET in Miami Beach, further enhancing the company's visibility among investors.
- Product Development Context: The pemvidutide being developed by Altimmune is a unique dual-action therapy targeting glucagon and GLP-1 receptors in a balanced 1:1 ratio, aimed at treating serious liver diseases such as metabolic dysfunction-associated steatohepatitis, indicating significant market potential.
- Information Access Channels: Investors can access the webcast of the fireside chats via the Events section of the Altimmune website, enhancing interaction with investors and improving transparency and trust.
See More
Altimmune Q1 2026 Earnings Call Insights
- Successful Financing: Altimmune completed an oversubscribed public offering in April, raising $225 million in gross proceeds, resulting in a cash balance of approximately $535 million as of April 30, which provides the company with sufficient funds to support its clinical programs through the critical data readout in 2029.
- Clinical Trial Progress: The company expects to initiate its global Phase III MASH trial, named PERFORMA, in the second half of this year, with data serving as the basis for regulatory submissions in multiple regions, marking a significant milestone in its global development strategy.
- Financial Performance: In Q1 2026, R&D expenses totaled $16.2 million, G&A expenses were $8.1 million, and the net loss amounted to $22.6 million, or $0.18 per share, indicating financial pressure while advancing clinical development.
- Future Outlook: Altimmune plans to report top-line data from the Phase II trial in alcohol use disorder next quarter and expects to complete enrollment for the RESTORE trial in ALD by Q3 2026, demonstrating positive progress across multiple clinical trials and confidence in future growth.
See More
Altimmune Reports Q1 2026 Financial Results and Progress on Pemvidutide
- Successful Financing: Altimmune completed an oversubscribed public offering in April, raising $225 million, significantly strengthening its financial foundation with a cash balance of approximately $535 million, ensuring funding for the MASH Phase III clinical trial in 2026.
- Clinical Trial Progress: The company plans to initiate the global Phase III clinical trial for MASH, named PERFORMA, in the second half of 2026, having submitted the final study protocol to the FDA, which is expected to support regulatory submissions across multiple regions, showcasing strategic positioning in liver disease treatment.
- Market Demand Analysis: Market research indicates that pemvidutide demonstrates favorable tolerability and efficacy in MASH patients, expected to address the growing unmet medical needs in this area, further solidifying Altimmune's competitive position in the biopharmaceutical market.
- Future Outlook: Altimmune is focused on executing its strategy, with top-line data from the AUD Phase II trial expected next quarter, further advancing the clinical development of pemvidutide and aiming to create long-term value for shareholders.
See More
